Table 1 Patient characteristics

From: An inflammatory cytokine signature predicts COVID-19 severity and survival

 

Patients with SARS-Cov-2 confirmed by PCR

Patients without SARS-Cov-2 confirmed by PCR

Median age (IQR)—years

63 (53–72)

60 (49–73)

Male

787/1,309 (60.1%)

90/167 (53.9%)

Race/ethnicity—Hispanic

577/1,268 (45.5%)

62/167 (37.1%)

Race/ethnicity—African American

278/1,268 (21.9%)

46/167 (27.5%)

Race/ethnicity—White

277/1,268 (21.8%)

43/167 (25.7%)

Race/ethnicity—Asian

73/1,268 (5.8%)

5/167 (3.0%)

Race/ethnicity—Other

63/1,268 (5.0%)

11/167 (6.6%)

Obesity (BMI ≥30)

465/1,176 (39.5%)

34/149 (22.8%)a

Comorbidities—hypertension

420/1,268 (33.1%)

67/167 (40.1%)

Comorbidities—diabetes

293/1,268 (23.1%)

34/167 (20.4%)

Comorbidities—CKD

167/1,268 (13.2%)

27/167 (16.2%)

Comorbidities—cancer (active)

147/1,267 (11.6%)

37/166 (22.3%)

Comorbidities—atrial fibrillation

123/1,267 (9.7%)

9/167 (5.4%)a

Comorbidities—CHF

69/1,268 (5.4%)

18/167 (10.8%)a

Comorbidities—asthma

72/1,268 (5.7%)

13/167 (7.8%)

Comorbidities—COPD

44/1,268 (3.5%)

18/167 (10.8%)

Comorbidities—sleep apnea

50/1,268 (3.9%)

6/167 (3.6%)

Smoking—current

55/965 (5.7%)

27/143 (18.9%)a

Smoking—history

293/965 (30.4%)

53/143 (37.1%)

SARS-CoV-2 PCR detected

1,257/1,257 (100.0%)

0/167 (0.0%)a

SARS-CoV-2 Ab detected

65/73 (89.0%)

3/5 (60.0%)

Maximum severity scoreb—mild/moderate

505/1,168 (43.2%)

99/150 (66.0%)a

Maximum severity scoreb—severe

285/1,168 (24.4%)

22/150 (14.7%)a

Maximum severity scoreb—severe with end organ damage

378/1,168 (32.4%)

29/150 (19.3%)a

SOFA score = 0

309/870 (35.5%)

42/119 (35.3%)

SOFA score = 1

163/870 (18.7%)

24/119 (20.2%)

SOFA score >1 (median = 4)

398/870 (45.7%)

53/119 (44.5%)

Acute respiratory distress syndrome

199/1,267 (15.7%)

11/167 (6.6%)a

Died within follow-up period

269/1,317 (20.4%)

13/167 (7.8%)a

  1. aSignificantly different between PCR-positive and PCR-negative subsets by Fisher’s exact test or chi-squared test.
  2. bSeverity score, described in Methods, is a composite measurement for COVID-19 established by Mount Sinai infectious disease and pulmonology teams based on criteria used in the literature and includes CrCl, ALT levels and use and type of respirators/ventilators and vasopressors (see Methods). Severity score indicated here is the maximum achieved throughout the observation period, but, for all other analyses, the severity score at the time of the first measurement was used. Denominator indicates number of patients with available information.
  3. CKD, chronic kidney disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; Ab, antibody.
Back to article page